Physician
Urology
Dr. Paul F. Siami, MD
|
|
Give Review
Paul Siami practices Urology. He attended University of Kentucky College of Medicine. University of Kentucky College of Medicine is ranked 63 in research and 72 in primary care medicine He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Paul Siami is a published MD. He has 24 publications published. The most current publication "BCG in management of transitional cell carcinoma invasive to prostate." Paul Siami accepts Medicare payments and is registered with Medicare.gov.
Publications
- Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long-term results from the combination of dutasteride and ta...
- Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive Bladder syndrome symptoms.
- Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract Infection.
- Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with Erectile dysfunction. The Apomorphine Study Group.
- False positive beta-human chorionic gonadotropin in testicular Cancer.
- Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characterist...
- Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive Bladder.
- The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results f...
- The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the C...
- Diary and patient-reported outcomes in patients with severe overactive Bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-l...
- Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hy...
- Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
- The influence of baseline parameters on changes in international Prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomati...
- Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.
- The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-ye...
- Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and Prostate enlargement: the CombAT (Combination of Av...
- Long-term treatment with darifenacin for overactive Bladder: results of a 2-year, open-label extension study.
- Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
- A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive Bladder: the speed of onset of therapeutic assessment trial (STAT).
- ''Acute on chronic'' effect of depot leuprolide in patients with stage D2 Cancer of prostate.
- Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial Bladder cancer.
- Urethral diverticular carcinoma.
- BCG in management of transitional cell carcinoma invasive to Prostate.
Procedures Preformed
- Complete Nephrectomy With Robotic Assistance
- Cystectomy
- Cystometry
- Cystotomy
- View All
Conditions Treated
- Balanoposthitis
- Bladder Atony
- Bladder Cancer
- Bladder Diseases
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Illinois College of Medicine at Chicago -
University of Kentucky College of Medicine -
Meharry Medical College
Drug Facts
| NPI NUMBER | 1639228513 | |
| NPPES Provider LastName | SIAMI | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 477131227 | |
| NPPES Provider State | IN | |
| Specialty Description | Urology | |
| Total Claim Count | 1756.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 105.0 | |
| Percent Opioid Claims | 5.98 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1639228513 |
| Last Name Of The Provider | SIAMI |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
Dr. Phillip M. Gilson, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Anvita Sinha, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph C. Klink, MD
This Doctor is OpenDoctor Recommended.
|